- Home
- XERS vs GLUE Comparison
XERS vs GLUE Comparison
Compare XERS & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | GLUE |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XERS | GLUE |
|---|---|---|
| Price | $8.23 | $22.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $10.83 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $49,590,000.00 | ★ $123,672,000.00 |
| Revenue This Year | $34.37 | N/A |
| Revenue Next Year | $22.86 | $2.45 |
| P/E Ratio | $821.00 | ★ $72.42 |
| Revenue Growth | ★ 142.67 | 63.54 |
| 52 Week Low | $4.87 | $4.12 |
| 52 Week High | $10.08 | $25.77 |
Technical Indicators
Market Signals| Indicator | XERS | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 47.73 |
| Support Level | $8.00 | $17.35 |
| Resistance Level | $8.42 | $25.38 |
| Average True Range (ATR) | 0.33 | 1.51 |
| MACD | -0.11 | -0.32 |
| Stochastic Oscillator | 24.00 | 27.51 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).